Patents for A61P 35 - Antineoplastic agents (221,099)
03/2007
03/13/2007US7189706 C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them
03/13/2007US7189696 Peptide antagonists of zonulin and methods for use of the same
03/13/2007US7189562 Mononuclear phagocytes in therapeutic drug delivery
03/13/2007US7189537 Comprises oncogenic nucleotide sequences for use in diagnosis, prevention and treatment of various cancers; gene therapy and antisense agents
03/13/2007US7189535 Modulators of the function of receptors of the TNF/NGF receptor family and other proteins
03/13/2007US7189525 Human enzymes of the metalloprotease family
03/13/2007US7189517 Goodpasture antigen binding protein
03/13/2007US7189389 Pharmaceutical composition of human interferon-α2 and interferon α8 subtypes
03/13/2007US7189383 Compounds with halogen for diagnosis with ethers or sulfides for cancer
03/13/2007CA2420895C Method for treating erectile dysfunction and increasing libido in men
03/13/2007CA2398182C Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
03/13/2007CA2274756C Methods and pharmaceutical compositions for inhibiting tumour cell growth
03/13/2007CA2267224C Vitronectin receptor antagonists
03/13/2007CA2264063C Cryptophycin compounds
03/13/2007CA2240494C Therapeutic molecules generated by trans-splicing
03/13/2007CA2222966C Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
03/13/2007CA2167578C Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor
03/13/2007CA2112866C Novel derivatives of 2-cyano-3-hydroxy-propenamides, a process for their preparation, their application as medicaments and pharmaceutical compositions containing them
03/13/2007CA1341522C Novel granulocyte colony stimulating factor polypeptide derivatives
03/08/2007WO2007028171A1 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
03/08/2007WO2007027834A1 Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
03/08/2007WO2007027729A1 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
03/08/2007WO2007027714A2 Engineered anti-il-23 antibodies
03/08/2007WO2007027594A1 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
03/08/2007WO2007027528A2 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-.receptor tyrosine kinases
03/08/2007WO2007026960A1 Use of mocs3 gene for therapeutic or diagnostic purposes
03/08/2007WO2007026869A1 Antitumor agent
03/08/2007WO2007026725A2 Drug, drug gudance system, magnetic detection system, and drug design method
03/08/2007WO2007026689A1 Antibody produced using ostrich and method for production thereof
03/08/2007WO2007026533A1 Soluble tablet containing nanosilicon particles and process for production thereof
03/08/2007WO2007026240A1 Sunscreen and cosmetic compositions for prophylaxis or treatment of skin cancers
03/08/2007WO2007026203A1 A pharmaceutical composition comprising mahanine useful for the treatment of prostate cancer
03/08/2007WO2007026201A1 A pharmaceutical composition useful for the treatment of prostate cancer
03/08/2007WO2007026157A1 Atm inhibitor
03/08/2007WO2007026146A1 Treatment using herpes simplex virus
03/08/2007WO2007026027A1 Novel ansamycin derivatives
03/08/2007WO2007025718A1 Oxadiazole compounds as urokinase inhibitors
03/08/2007WO2007025534A1 Fredericamycin derivatives
03/08/2007WO2007025388A2 Anti-apoptotic protein antibodies
03/08/2007WO2007025365A1 Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
03/08/2007WO2007011216A3 Bifunctional protein anchors
03/08/2007WO2007011216A2 Bifunctional protein anchors
03/08/2007WO2007009395A8 Schisandrin b preparation
03/08/2007WO2007005668A3 Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
03/08/2007WO2007004869A3 Treatment of tumors
03/08/2007WO2006137009A3 Fluorescent sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as therapeutic and diagnostic agents
03/08/2007WO2006125539A3 Combination therapy comprising diaryl ureas for treating diseases
03/08/2007WO2006110175A3 Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
03/08/2007WO2006108682A3 Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents
03/08/2007WO2006105021A3 Gitr binding molecules and uses therefor
03/08/2007WO2006099445A3 Nanocells for diagnosis and treatment of diseases and disorders
03/08/2007WO2006074451A3 Targeted chimeric molecules for cancer therapy
03/08/2007WO2006071983A3 Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
03/08/2007WO2006038101A3 Novel cancer associated antibodies and antigens and their use in cancer diagnosis
03/08/2007WO2005110486A3 7-t-butoxyiminomethylcamptothecin conjugated in position 20 with integrin antagonists
03/08/2007WO2004026846A8 Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy
03/08/2007WO2003047611A8 Ptp10d, tec and edtp involved in triglycerid-metabolism
03/08/2007WO2003020702A3 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
03/08/2007US20070055459 Structure-based approach to design of protein-processivity factor interactions
03/08/2007US20070054956 6-(4-Methoxy-phenyl)-5-{4-[4-(4,4,5,5,5-pentafluoropentylsulfanyl/ pentafluoropentanesulfinyl)-butoxy]-phenoxy}-naphthalen-2-ol; anticarcinogenic agent; breast cancer, metastases to the bone or brain, radiation fibrosis and neutropenic sepsis
03/08/2007US20070054923 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
03/08/2007US20070054922 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
03/08/2007US20070054920 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
03/08/2007US20070054904 Phenol derivatives and their use as rotamase inhibitors
03/08/2007US20070054902 Isoxazole derivatives as peroxisome proliferator-activated receptors agonists
03/08/2007US20070054899 Aromatase inhibitor compounds and uses thereof
03/08/2007US20070054898 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
03/08/2007US20070054895 e.g. 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1H-indole or salts for treating colon cancer
03/08/2007US20070054861 Therapeutic uses of SMR1 peptides
03/08/2007US20070054364 Polypeptide variants
03/08/2007US20070054363 nucleotide sequences coding protein of urogenital system for identifying modulators for treatment of cell proliferative and metastatic disorders
03/08/2007US20070054328 Methods
03/08/2007US20070054312 Human transmembrane proteins
03/08/2007US20070054284 Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer
03/08/2007US20070053922 Epitope based vaccines directed towards HPV; side effect reduction; vaccination
03/08/2007US20070053915 GIPs, a family of polypeptides with transcription factor activity that interact with Goodpasture antigen binding protein
03/08/2007US20070053905 treating chondroma and chondrosarcoma by administering humanized anti-PTHrP(1-34) antibody which inhibits binding of parathyroid hormone related peptide to a receptor thereof
03/08/2007US20070053902 Anti-alphabeta3 humanized monoclonal antibodies
03/08/2007US20070053836 Cytotoxicity mediation of cells evidencing surface expression of CD44
03/08/2007US20070053833 Hydrating a leukemia patient; parenterally administering a dose samarium ethylenediaminetetramethylenephosphonic acid (EDTMP); and melphalan, busulfan, and/or cyclophosphamiide; anticarcinogenic, antitumor, and antantiproliferative agents; autoimmune, infectious , metabolic or genetic disorders
03/08/2007DE19958198B4 Mit dem IGF-1 Rezeptor wechselwirkende Proteine (IIPs) With the IGF-1 receptor interacting proteins (IIPs)
03/08/2007DE102005041760A1 New fredericamycin A derivatives with carbon-bonded B-ring substituent, are well tolerated topoisomerase I and/or II inhibitors especially useful for treating cancers or tumors
03/08/2007DE102005041616A1 Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und deren Verwendungen Melanoma-associated MHC class I-associated oligopeptides and their uses
03/08/2007DE102005041613A1 Use of octahydro-indolo-quinoline compound in the preparation of pharmaceutical composition for the treatment and prophylaxis of gastrointestinal and endocardial disease and carcinoid syndrome
03/08/2007CA2848021A1 Compostions and methods for preparation of poorly water soluble drugs with increased stability
03/08/2007CA2845095A1 methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
03/08/2007CA2825762A1 Method for enhancing anti-neoplastic activity of an oncolytic virus using modified dendritic cells
03/08/2007CA2625951A1 Anti-apoptotic protein antibodies
03/08/2007CA2621377A1 Antitumor agent
03/08/2007CA2621136A1 Immunological uses of immunodulatory compounds for vaccine and anti-infectious disease therapy
03/08/2007CA2621127A1 Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
03/08/2007CA2621083A1 Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
03/08/2007CA2620915A1 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
03/08/2007CA2620864A1 Raf inhibitor compounds and methods of use thereof
03/08/2007CA2620802A1 Engineered anti-il-23 antibodies
03/08/2007CA2620683A1 Oxadiazole compounds as urokinase inhibitors
03/08/2007CA2620631A1 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-.receptor tyrosine kinases
03/08/2007CA2620352A1 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
03/08/2007CA2620269A1 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
03/08/2007CA2620023A1 Novel ansamycin derivatives